openPR Logo
Press release

Ajinomatrix launches the free MP6 Converter - turning sensory spreadsheets into a portable, open sensory file format

05-27-2026 09:26 AM CET | Food & Beverage

Press release from: AJINOMATRIX.ORG

Find the App on mp6.app

Find the App on mp6.app

A browser-based tool that converts panel and instrument data into ".mp6", a single-file open format describing how a product is perceived across six senses.
Rebecq, Belgium - 27 May 2026 - Ajinomatrix today released the MP6 Converter V0.1, a free, browser-based tool that converts sensory-evaluation spreadsheets into .mp6 - a single-file, portable, open format for describing how a product is perceived across six dimensions: sight, smell, taste, touch, sound and intuition.
Sensory data in the food & beverage (F&B) and flavor & fragrance (F&F) industries is some of the richest data a company owns - and some of the most trapped. Every lab, panel and supplier formats its spreadsheets differently: wide panels, descriptor-by-product matrices, time-series, GC-MS compound tables. The result is data that is hard to compare, hard to share, and hard to reuse. The MP6 Converter addresses this by translating those varied spreadsheets into one consistent, self-contained file per product.

What the MP6 Converter does
• Reads what labs already produce. Upload one or many .xlsx, .xls, .ods or .csv files. The tool auto-detects the layout of each sheet - wide panel, QDA matrix, long, temporal - and lets the user override it.
• Maps the vocabulary. A built-in English/French sensory dictionary maps descriptors to MP6 dimensions; every mapping is editable, and descriptors that don't match a known term are preserved, never discarded.
• Aggregates and normalises. Each attribute is summarised (mean, standard deviation, count, min, max) and normalised to a common 0-10 scale.
• Exports portable files. It produces one .mp6 file per product - JSON inside, with a clear .mp6 extension - downloadable individually or as a ZIP. Each filename carries the usage grade and product name.

The converter runs entirely in the user's browser. Uploaded spreadsheets are processed in memory and are never sent to a server or stored - a deliberate privacy-by-design choice for labs handling confidential formulation data.
Optional AI-assisted mapping

For descriptors that the built-in dictionary cannot resolve automatically, the converter offers an optional AI-assisted mapping step that connects to Anthropic's Claude API. This feature is entirely opt-in: the user supplies their own Anthropic API key, which is held in memory for the request only and never stored. The converter is fully functional without it.

Who it is for
The MP6 Converter is aimed at sensory analysts, R&D and product-development teams, flavourists and perfumers, quality labs, and artisan producers - chocolatiers, bakers, brewers and chefs - who want a consistent, shareable way to record and exchange sensory profiles.

What comes next
V0.1 is the first piece of a planned ecosystem of companion applications built around the MP6 format. Several are in early development, including with collaborator Vincent Leurs:

• MP6 Viewer & Validator - open and structurally check .mp6 files.
• Sensory Radar Renderer - turn evaluations into multiple-axis radar charts.
• MP6 Timeline Player - replay a sensory sequence over time, from attack to aftertaste.
• Panel Data Comparator - compare two products or formulations side by side.
• Recipe Passport - a public, MP6-backed sensory page for a product or recipe.
These are roadmap items; availability and timing will be announced separately.

Quote
"Sensory evaluation produces extraordinary data, but too often it dies in a spreadsheet that no two labs format the same way," said François, founder of Ajinomatrix. "MP6 is a simple idea: one portable file that carries a product's full sensory profile, readable by humans and machines alike. The converter is our way of putting that idea in everyone's hands - for free - and inviting the industry to try it."

Availability
The MP6 Converter V0.1 is available now as a free web application. MP6 is an open format proposed by Ajinomatrix; V0.1 files are converter outputs and are not certified by any standards body.

Drève de la Chapelle, 34
1430 Rebecq
BELGIUM
EUROPE

Ajinomatrix develops sensory-data tools and the MP6 open file format for the food, beverage, flavor and fragrance industries. Ajinomatrix develops AI-assisted sensory intelligence tools for food, beverage, recipe, product development, and consumer evaluation workflows. Beyond MP6, the wider Ajinomatrix toolset includes TasteTuner, RecipeAnalyzer, Chef Paradous / TTP-style public evaluation flows, and AjinoVerse sensory suite's modules designed to connect sensory data, recipe/process graphs, consumer feedback, and decision-support into one interoperable ecosystem.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ajinomatrix launches the free MP6 Converter - turning sensory spreadsheets into a portable, open sensory file format here

News-ID: 4528143 • Views:

More Releases for MP6

Fabry Disease Market Estimated at USD 1.7 Billion in 2024, Reports DelveInsight
Leading organizations engaged in the Fabry disease domain include Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, CellGenTech, and several others. During 2024, the United States dominated the Fabry disease therapeutics landscape, capturing nearly 52% of the overall 7MM market and generating close to USD 880 million in revenue, making it the top regional
Fabry Disease Market Valued at USD 1.7 Billion in 2024, According to DelveInsigh …
Key companies active in the Fabry Disease space include Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, and CellGenTech. DelveInsight estimates that the Fabry Disease market reached a value of USD 1.7 billion in 2024. In the same year, the United States led the Fabry Disease therapeutics market, accounting for approximately 52% of the
Fabry Disease Market Outlook 2034 - Clinical Trials, Market Size, Medication, Pr …
Fabry Disease companies are Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, CellGenTech, and others. Fabry Disease Market Summary The Fabry Disease Treatment Market was valued at approximately USD 1.7 billion in 2024, with the US accounting for ~52% (~USD 880 million) of the 7MM market. Fabry disease is a rare X-linked disorder caused by
Fabry Disease Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, …
Fabry Disease companies are Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, CellGenTech and others. (Albany, USA) DelveInsight's "Fabry Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU5 (Germany, Spain, Italy,
Fabry Disease Treatment Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, …
Fabry Disease companies are Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, CellGenTech, others (Albany, USA) DelveInsight's "Fabry Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU5 (Germany, Spain, Italy, France,
Fabry Disease Market Forecast 2032: FDA Approvals, Clinical Trials, Pipeline, Ep …
Fabry Disease companies are Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, CellGenTech, and others (Albany, USA) DelveInsight's "Fabry Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU5 (Germany, Spain, Italy,